// App-Quantinova.ai

2527 : A phase 1 dose-escalation study of BBI503, a first-in-class cancer stemness kinase inhibitor in adult patients with advanced solid tumors.

Researchers

Presenter

  • Scott Andrew Laurie

Principal Investigators

  • Derek J. Jonker

  • Matthew Hitron

  • Wei Li

  • Youzhi Li

  • Keyur Gada

  • Yuan Gao

  • Chiang Li

Medical Centers

  • Ottawa Hospital Cancer Centre, Ottawa, ON, Canada

  • Boston Biomedical, Inc., Cambrige, MAThe Ottawa Hospital Research Institute, Ottawa, ON, CanadaOttawa Hospital Research Institute, Ottawa, ON, Canada

  • Institute for Translational Oncology Research, Greenville, SC

  • Boston Biomedical Inc., Cambridge, MA

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • BBI-503

Outcome

  • Positive

Study Design

  • pharmacokinetics

Phase

  • I

Study Id's

  • NCT01781455

Sponsors

  • Boston Biomedical, Inc.

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved